Oncology

Researchers compared lung cancer care and outcomes, including patient characteristics, stage of cancer at diagnosis, treatment, and overall survival of patients in the United States and England.

Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

Officials with the FDA alerted health care professionals about reduced efficacy for some patients taking pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for metastatic urothelial cancer in ongoing clinical trials.

Top news of the day from across the health care landscape.

At the National Community Oncology Dispensing Association's (NCODA) 2018 Spring Summit, Julianne Orr, PharmD, from Indiana University Health Simon Cancer Center, discusses the pharmacist's role in managing adherence to oral treatment regimens for patients with cancer.

Although nearly every state has some type of rule governing coverage of oncology drugs, the question that continually pops up is whether these rules matter when it comes to formulary inclusion.

CAR T-cell immunotherapy is being hailed as the fifth pillar of cancer treatment.

Specialty pharmacists need to fully understand capecitabine’s place in colorectal cancer treatment to ensure that it is safely and effectively utilized.

The high-level monitoring required for self-managing patients with cancer becomes a challenge when patients are seen less frequently by their provider.

Market access and health care professionals must work to find the balance to provide solid treatment for cancer without burdening the system to a point of collapse.

Oncology economics is the product of driving forces in the health insurance market that are intrinsic to oncology in managed care and unlikely to change.

There is an ongoing shift toward many cancer types being treated as maintenance diseases, which places a significant financial burden not only on patients, but also payers and providers within the health care industry.

Health care providers—including physicians, oncologists, and specialty pharmacists—must leverage their collective resources and expertise to work together to address adherence on a larger scale. 

Following their approval, anti–PD-1 agents reach a significant proportion of patients within a few months, according to new study findings.

Top news of the day from across the health care landscape.

The recommendation means more men could be screened, now that the recommendation has been upgraded from its existing D recommendation to a grade C recommendation.

Researchers found that women with advanced triple-negative breast cancer who had inherited a BRCA mutation benefited more from the chemotherapy carboplatin than standard treatment.

A new study examines how chemoresistance evolves over time, which could lead to improved patient outcomes and survival.

A dual immune-checkpoint blockade efficiently controlled the development of chronic lymphocytic leukemia by restoring functional antitumor immune response.

The development and uptake of antiretroviral therapy for HIV has reduced the risk of certain cancers were previously prevalent.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

BLU-667 is being investigated for the treatment of cancers caused by an alteration in the receptor tyrosine kinase.

The new method indexes thousands of cells simultaneously and could potentially improve understanding of various diseases at a molecular level.

The findings suggest that a patient’s diet may impact their ability to combat head and neck cancer.

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

Unintentional weight loss may allow physicians to detect cancer sooner.

A review found an elevated risk of cancer progression with increasing wait time between positive screening and start of diagnostic testing.